CI

At a glance

ClinicalIndex Comparison Record
Phase 2Active· 85 enrolled
Drug / intervention
Ibrutinib +3 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02251548
NCT02251548Phase 2Active
CompareCT.gov

A Phase II Study of Ibrutinib in Combination With Fludarabine, Cyclophosphamide, and Rituximab (iFCR) in Previously Untreated, Younger Patients With Chronic Lymphocytic Leukemia

Dana-Farber Cancer Institute·interventional·Posted Sep 29, 2014·Updated Oct 24, 2025

In Brief

A Phase 2 clinical trial evaluating Ibrutinib, Fludarabine, and 2 other interventions for Chronic Lymphocytic Leukemia and Leukemia. Active but no longer recruiting, targeting 85 participants across 9 sites.

Detailed Summary

This research study is evaluating a new drug called ibrutinib in combination with the standard drugs fludarabine, cyclophosphamide, and rituximab (FCR) as a possible treatment for Chronic Lymphocytic Leukemia (CLL).

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsChronic Lymphocytic Leukemia, Leukemia
CountriesUnited States
CollaboratorsPharmacyclics LLC., The Leukemia and Lymphoma Society, Blood Cancer Research Partnership

Timeline

Phase 2Active
2015201620172018201920202021202220232024202520262027
First PostedSep 29, 2014
Enrollment StartOct 1, 2014
Primary CompletionJan 1, 2025
Study CompletionJan 1, 2027
TodayJul 2, 2026
Enrollment to primary: 10.3 yearsPosted 11.8 years ago

Interventions

Ibrutinibdrug

Oral BTK inhibitor

Fludarabinedrug

IV purine analogue chemotherapy agent

Cyclophosphamidedrug

IV alkylator chemotherapy agent

Rituximabdrug

IV anti-CD20 monoclonal antibody